Business Description
Arch Biopartners Inc
NAICS : 325412
SIC : 3741
ISIN : CA03938C1041
Description
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | -8.98 | |||||
| Debt-to-Equity | -0.88 | |||||
| Debt-to-EBITDA | -3.2 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 13.4 | |||||
| 3-Year EPS without NRI Growth Rate | 11.7 | |||||
| 3-Year FCF Growth Rate | 50 | |||||
| 3-Year Book Growth Rate | -11.2 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 3.96 | |||||
| 9-Day RSI | 14.99 | |||||
| 14-Day RSI | 28.06 | |||||
| 6-1 Month Momentum % | 119.44 | |||||
| 12-1 Month Momentum % | 13.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.11 | |||||
| Quick Ratio | 0.11 | |||||
| Cash Ratio | 0.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1 | |||||
| Shareholder Yield % | -0.71 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -127.85 | |||||
| ROIC % | -41.93 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -78.93 | |||||
| EV-to-EBITDA | -78.93 | |||||
| EV-to-Forward-Revenue | 62.08 | |||||
| EV-to-FCF | -69.71 | |||||
| Earnings Yield (Greenblatt) % | -1.27 | |||||
| FCF Yield % | -1.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arch Biopartners Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -0.031 | ||
| Beta | 2.04 | ||
| Volatility % | 77.32 | ||
| 14-Day RSI | 28.06 | ||
| 14-Day ATR (C$) | 0.089014 | ||
| 20-Day SMA (C$) | 2.307 | ||
| 12-1 Month Momentum % | 13.94 | ||
| 52-Week Range (C$) | 0.97 - 2.56 | ||
| Shares Outstanding (Mil) | 62.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arch Biopartners Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arch Biopartners Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arch Biopartners Inc Frequently Asked Questions
What is Arch Biopartners Inc(TSXV:ARCH)'s stock price today?
The current price of TSXV:ARCH is C$1.90. The 52 week high of TSXV:ARCH is C$2.56 and 52 week low is C$0.97.
When is next earnings date of Arch Biopartners Inc(TSXV:ARCH)?
The next earnings date of Arch Biopartners Inc(TSXV:ARCH) is .
Does Arch Biopartners Inc(TSXV:ARCH) pay dividends? If so, how much?
Arch Biopartners Inc(TSXV:ARCH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers